aap Implantate AG: Interim Q1/2002 figures

15% growth in sales revenues / EBITDA increase ex stock option 118% / Turnaround already achieved / Restructuring program shows clear successes

aap Implantate AG, the metal and biological implant specialist for the muscular-skeletal system, increased sales revenues in the first quarter of 2002 by roughly 15% on the year to approximately € 3.42 million from € 2.98 million. EBITDA excluding stock options was up roughly 118% to roughly € 1.2 million (previous: € 540,000). Not counting acquisition-related depreciations totaling € 365,000 (previous: € 403,000) and stock options totaling € 170,000 (previous: € 208,000), EBIT amounted to € 895,000 (previous: € 232,000). Including the above-mentioned special effects (stock options and acquisition-related depreciations), EBIT was € 361,000 (previous: -€ 379,000).

The figures reconfirm the previously stated outlook for 2002 of double-digit growth in sales revenues and a net profit for the year without the above-mentioned special effects. aap Implantate AG will be announcing detailed figures on May 31 when the 3 monthly report is published.